Drugs / RBC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT06495294 | Dec 2024 → Dec 2026 expected | — | Unity Health Toronto | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RBC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06495294 ↗ |
| Route | Intravenous | “RBC and plasma may be administered via either the intravenous (IV) or intraosseous (IO) route, according to standard clinical practice at Ornge AAS.” NCT06495294 ↗ |
| Route | Other | “RBC and plasma may be administered via either the intravenous (IV) or intraosseous (IO) route, according to standard clinical practice at Ornge AAS.” NCT06495294 ↗ |